Definium Therapeutics, Inc. (DFTX)
NASDAQ: DFTX · Real-Time Price · USD
43.27
-1.64 (-3.65%)
At close: Aug 24, 2026, 4:00 PM EDT
43.25
-0.02 (-0.05%)
After-hours: Aug 24, 2026, 7:56 PM EDT

Definium Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
72.948.6438.6241.7430.1658.77
Research & Development
154.65117.6765.352.1236.1734.79
Operating Expenses
227.54166.31103.9293.8766.3393.55
Operating Income
-227.54-166.31-103.92-93.87-66.33-93.55
Interest Expense
-5.02-5.48-2.28-0.92--0.36
Interest & Investment Income
12.810.9611.565.581.5-
Currency Exchange Gain (Loss)
-0.14-0.13-0.640.160.2-0.09
Other Non Operating Income (Expenses)
-133.88-22.83-15.94-6.697.850.11
EBT Excluding Unusual Items
-353.79-183.79-111.22-95.73-56.8-93.89
Merger & Restructuring Charges
------0.3
Other Unusual Items
--2.54---
Pretax Income
-353.79-183.79-108.68-95.73-56.8-94.19
Income Tax Expense
------1.16
Net Income
-353.79-183.79-108.68-95.73-56.8-93.04
Net Income to Common
-353.79-183.79-108.68-95.73-56.8-93.04
Net Income Growth
------
Shares Outstanding (Basic)
1028970393127
Shares Outstanding (Diluted)
1028970393127
Shares Change
22.22%26.78%79.94%26.90%12.71%54.25%
EPS (Basic)
-3.48-2.06-1.54-2.44-1.84-3.40
EPS (Diluted)
-3.48-2.06-1.54-2.44-1.84-3.40
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EBITDA
--166.28-103.89--66.32-93.54
D&A For EBITDA
-0.030.03-0.020.02
EBIT
-227.54-166.31-103.92-93.87-66.33-93.55